Search results
Results From The WOW.Com Content Network
Ceftriaxone, sold under the brand name Rocephin, is a third-generation cephalosporin antibiotic used for the treatment of a number of bacterial infections. [4] These include middle ear infections, endocarditis, meningitis, pneumonia, bone and joint infections, intra-abdominal infections, skin infections, urinary tract infections, gonorrhea, and pelvic inflammatory disease. [4]
Biliary pseudolithiasis is an unusual complication of ceftriaxone where the drug complexes with calcium and mimics gallstones. [1] [2] It is reversed when ceftriaxone administration is stopped. [2] It was first described in 1988 by Schaad et al. as "reversible ceftriaxone-associated biliary pseudolithiasis".
First and third-generation cephalosporins, like cefalexin and ceftriaxone, are more commonly used in clinical practice. [17] Common adverse effects associated with cephalosporins include hypersensitivity, rash, anaphylaxis, and seizures. [12] Penicillin is another widely used subclass that effectively targets various bacteria. [18]
For ceftriaxone, the color of solutions can range from light yellow to amber, depending on the length of storage, concentration, and diluent used. [30] [31] A study found that meropenem concentrations dropped to 90% of the initial concentration at 7.4 hours at 22°C and 5.7 hours at 33°C, indicating degradation over time. [29]
Ceftaroline fosamil / s ɛ f ˈ t ær oʊ l iː n /, brand name Teflaro in the US and Zinforo in Europe, [1] [2] is a cephalosporin antibiotic with anti-MRSA activity. [3] Ceftaroline fosamil is a prodrug of ceftaroline.
Cephalosporins are a broad class of bactericidal antibiotics that include the β-lactam ring and share a structural similarity and mechanism of action with other β-lactam antibiotics (e.g. penicillins, carbapenems and monobactams). [1]
A drug in blood exists in two forms: bound and unbound. Depending on a specific drug's affinity for plasma proteins, a proportion of the drug may become bound to the proteins, with the remainder being unbound.
Pfizer divided them into two groups and treated half with Trovan. (Compl. P 3.) The other half was "purposefully 'low-dosed'" with ceftriaxone, an FDA-approved drug shown to be effective in treating meningitis. (Compl. P 125.) In order to enhance the comparative results of Trovan, Pfizer administered only one-third of ceftriaxone's recommended ...